1. Home
  2. MRKR vs TXMD Comparison

MRKR vs TXMD Comparison

Compare MRKR & TXMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • MRKR
  • TXMD
  • Stock Information
  • Founded
  • MRKR N/A
  • TXMD 2008
  • Country
  • MRKR United States
  • TXMD United States
  • Employees
  • MRKR N/A
  • TXMD N/A
  • Industry
  • MRKR Biotechnology: Pharmaceutical Preparations
  • TXMD Biotechnology: Pharmaceutical Preparations
  • Sector
  • MRKR Health Care
  • TXMD Health Care
  • Exchange
  • MRKR Nasdaq
  • TXMD Nasdaq
  • Market Cap
  • MRKR 11.6M
  • TXMD 12.3M
  • IPO Year
  • MRKR N/A
  • TXMD N/A
  • Fundamental
  • Price
  • MRKR $1.02
  • TXMD $1.19
  • Analyst Decision
  • MRKR Strong Buy
  • TXMD
  • Analyst Count
  • MRKR 3
  • TXMD 0
  • Target Price
  • MRKR $13.17
  • TXMD N/A
  • AVG Volume (30 Days)
  • MRKR 317.3K
  • TXMD 449.4K
  • Earning Date
  • MRKR 11-13-2025
  • TXMD 11-11-2025
  • Dividend Yield
  • MRKR N/A
  • TXMD N/A
  • EPS Growth
  • MRKR N/A
  • TXMD N/A
  • EPS
  • MRKR N/A
  • TXMD N/A
  • Revenue
  • MRKR $5,388,071.00
  • TXMD $2,559,000.00
  • Revenue This Year
  • MRKR N/A
  • TXMD $427.09
  • Revenue Next Year
  • MRKR $9.35
  • TXMD N/A
  • P/E Ratio
  • MRKR N/A
  • TXMD N/A
  • Revenue Growth
  • MRKR 44.55
  • TXMD 156.93
  • 52 Week Low
  • MRKR $0.81
  • TXMD $0.70
  • 52 Week High
  • MRKR $5.95
  • TXMD $2.44
  • Technical
  • Relative Strength Index (RSI)
  • MRKR 51.53
  • TXMD 75.50
  • Support Level
  • MRKR $0.97
  • TXMD $0.99
  • Resistance Level
  • MRKR $1.08
  • TXMD $1.09
  • Average True Range (ATR)
  • MRKR 0.07
  • TXMD 0.08
  • MACD
  • MRKR 0.01
  • TXMD 0.01
  • Stochastic Oscillator
  • MRKR 60.50
  • TXMD 36.62

About MRKR Marker Therapeutics Inc.

Marker Therapeutics Inc is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies and peptide-based vaccines for the treatment of hematological malignancies and solid tumor indications. The company develops product candidates from its MultiTAA T cell technology, which is based on the selective expansion of non-engineered, tumor-specific T cells that recognize tumor-associated antigens, or TAAs, which are tumor targets, and then kill tumor cells expressing those targets.

About TXMD TherapeuticsMD Inc.

TherapeuticsMD Inc is a pharmaceutical royalty company, currently receiving royalties on products licensed to pharmaceutical organizations that possess commercial capabilities in the relevant territories. The company and its subsidiaries (i) granted Mayne Pharma an exclusive license to commercialize its IMVEXXY, BIJUVA and prescription prenatal vitamin products sold under the BocaGreenMD and vitaMedMD brands (collectively, the "Licensed Products") in the United States and its possessions and territories, (ii) assigned to Mayne Pharma its exclusive license to commercialize ANNOVERA (together with the Licensed Products, collectively, the "Products") in the United States and its possessions and territories.

Share on Social Networks: